spacer
home > pmps > autumn 2008 > a revolution in aseptic filling
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

A Revolution in Aseptic Filling

The aseptic filling of injectable drugs has always been a challenge for the pharmaceutical industry. Contamination accidents, despite being rare, are still recorded among the 20 billion injections and infusions made every year in the world.

In a recent market study, six per cent of hospital professionals in Europe and the US reported that they have already faced at least one case of contaminated vials. In recent years, the authorities have taken a radical turn to strongly support the most advanced aseptic filling technologies, such as the use of isolators, whereas the use of classical processes in an Iso 5/Grade A cleanroom are more and more questioned, as the risks caused by proximity of operators to the open containers becomes evident...


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Benoоt Verjans has a PhD degree in Biochemistry and a MBA from the University of Brussels. He has developed a post-doctoral programme at the University of Cambridge (UK). He worked at UCB Pharma in International Marketing, at McKinsey and Co as a consultant, in the pharma sector (marketing, supply chain and licensing projects), and as CEO of 4AZA Bioscience, a start-up from the University of Leuven developing new immuno-modulating drugs. He is currently Commercial Director of Aseptic Technologies, responsible for developing the sales of closed vial technology worldwide. He is on the Editorial Board of Pharmaceutical Technology Europe and a member of ISPE.
spacer
Benoоt Verjans
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma enters into Development and Manufacturing Agreement with Synklino

Vilnius, Lithuania, and Copenhagen, Denmark – December 18th 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Synklino, a company active in developing a therapeutic protein based therapy as treatment for cytomegalovirus (CMV) infection, announced today that they entered into a Development and Manufacturing Agreement for the recombinant fusion protein SYNx, which Synklino aims to bring into clinical trials.
More info >>

White Papers

Comparator Sourcing in Oncology Trials

Clinical Services International

This is an exciting time for oncology trials, year on year record numbers of therapeutics are launched and the indications for many drugs on the market are increasing rapidly. Immunotherapies and next generation biotherapeutics are being approved for more tumour types and a growing percentage of the late stage oncology pipeline are targeted biologics.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement